SUZHOU, CHINA & WASHINGTON D.C. – May 26, 2025 – A truly revolutionary stride in neuroregenerative medicine is officially underway, promising a profound paradigm shift in the treatment of spinal cord injuries (SCI). XellSmart Biopharmaceutical today announced a landmark moment: the official dual approval by both the U.S. Food and
LAUSANNE, SWITZERLAND – May 11, 2025 – A groundbreaking clinical trial at NeuroRestore in Lausanne, Switzerland, is offering unprecedented hope for individuals with severe spinal cord injuries. Led by renowned French neuroscientist Grégoire Courtine and Swiss neurosurgeon Dr. Jocelyne Bloch, researchers have developed a "digital bridge" that wirelessly connects a
WASHINGTON D.C. – December 30, 2024 – A new and profoundly hopeful era in spinal cord injury (SCI) rehabilitation has officially dawned with the U.S. Food and Drug Administration (FDA) clearance of ONWARD Medical's groundbreaking external ARC-EX spinal cord stimulation system. This monumental approval signifies the first time